Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Insights into JAK Inhibitor Use

  |  Issue: February 2022  |  

References

  1. Risser L, Witte T. Bartz-Bazanella P, et al. Persistence on JAK inhibitors in daily practice: Evaluation of the Rhadar-registry [abstract 0841]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
  2. Kleinert S, Bartz-Bazzanella P, von der Decken C, et al. A real-world rheumatology registry and research consortium: The German RheumaDatenRhePort (RHADAR) Registry. J Med Internet Res. 2021 May 20;23(5):e28164.
  3. Rheumatoid arthritis: Causes, symptoms, treatments and more. Arthritis Foundation. 2021 Oct 15.

 

 

ADVERTISEMENT
SCROLL TO CONTINUE

 

 

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Are We Playing It Safe?

    Tumor necrosis factor alpha inhibition and the risk of solid malignancies

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…